Cargando…
Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients
BACKGROUND: Risk prediction models for colorectal cancer (CRC) detection in symptomatic patients based on available biomarkers may improve CRC diagnosis. Our aim was to develop, compare with the NICE referral criteria and externally validate a CRC prediction model, COLONPREDICT, based on clinical an...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007726/ https://www.ncbi.nlm.nih.gov/pubmed/27580745 http://dx.doi.org/10.1186/s12916-016-0668-5 |
_version_ | 1782451262147526656 |
---|---|
author | Cubiella, Joaquín Vega, Pablo Salve, María Díaz-Ondina, Marta Alves, Maria Teresa Quintero, Enrique Álvarez-Sánchez, Victoria Fernández-Bañares, Fernando Boadas, Jaume Campo, Rafel Bujanda, Luis Clofent, Joan Ferrandez, Ángel Torrealba, Leyanira Piñol, Virginia Rodríguez-Alcalde, Daniel Hernández, Vicent Fernández-Seara, Javier |
author_facet | Cubiella, Joaquín Vega, Pablo Salve, María Díaz-Ondina, Marta Alves, Maria Teresa Quintero, Enrique Álvarez-Sánchez, Victoria Fernández-Bañares, Fernando Boadas, Jaume Campo, Rafel Bujanda, Luis Clofent, Joan Ferrandez, Ángel Torrealba, Leyanira Piñol, Virginia Rodríguez-Alcalde, Daniel Hernández, Vicent Fernández-Seara, Javier |
author_sort | Cubiella, Joaquín |
collection | PubMed |
description | BACKGROUND: Risk prediction models for colorectal cancer (CRC) detection in symptomatic patients based on available biomarkers may improve CRC diagnosis. Our aim was to develop, compare with the NICE referral criteria and externally validate a CRC prediction model, COLONPREDICT, based on clinical and laboratory variables. METHODS: This prospective cross-sectional study included consecutive patients with gastrointestinal symptoms referred for colonoscopy between March 2012 and September 2013 in a derivation cohort and between March 2014 and March 2015 in a validation cohort. In the derivation cohort, we assessed symptoms and the NICE referral criteria, and determined levels of faecal haemoglobin and calprotectin, blood haemoglobin, and serum carcinoembryonic antigen before performing an anorectal examination and a colonoscopy. A multivariate logistic regression analysis was used to develop the model with diagnostic accuracy with CRC detection as the main outcome. RESULTS: We included 1572 patients in the derivation cohort and 1481 in the validation cohorts, with a 13.6 % and 9.1 % CRC prevalence respectively. The final prediction model included 11 variables: age (years) (odds ratio [OR] 1.04, 95 % confidence interval [CI] 1.02–1.06), male gender (OR 2.2, 95 % CI 1.5–3.4), faecal haemoglobin ≥20 μg/g (OR 17.0, 95 % CI 10.0–28.6), blood haemoglobin <10 g/dL (OR 4.8, 95 % CI 2.2–10.3), blood haemoglobin 10–12 g/dL (OR 1.8, 95 % CI 1.1–3.0), carcinoembryonic antigen ≥3 ng/mL (OR 4.5, 95 % CI 3.0–6.8), acetylsalicylic acid treatment (OR 0.4, 95 % CI 0.2–0.7), previous colonoscopy (OR 0.1, 95 % CI 0.06–0.2), rectal mass (OR 14.8, 95 % CI 5.3–41.0), benign anorectal lesion (OR 0.3, 95 % CI 0.2–0.4), rectal bleeding (OR 2.2, 95 % CI 1.4–3.4) and change in bowel habit (OR 1.7, 95 % CI 1.1–2.5). The area under the curve (AUC) was 0.92 (95 % CI 0.91–0.94), higher than the NICE referral criteria (AUC 0.59, 95 % CI 0.55–0.63; p < 0.001). On the basis of the thresholds with 90 % (5.6) and 99 % (3.5) sensitivity, we divided the derivation cohort into three risk groups for CRC detection: high (30.9 % of the cohort, positive predictive value [PPV] 40.7 %, 95 % CI 36.7–45.9 %), intermediate (29.5 %, PPV 4.4 %, 95 % CI 2.8–6.8 %) and low (39.5 %, PPV 0.2 %, 95 % CI 0.0–1.1 %). The discriminatory ability was equivalent in the validation cohort (AUC 0.92, 95 % CI 0.90–0.94; p = 0.7). CONCLUSIONS: COLONPREDICT is a highly accurate prediction model for CRC detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0668-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5007726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50077262016-09-02 Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients Cubiella, Joaquín Vega, Pablo Salve, María Díaz-Ondina, Marta Alves, Maria Teresa Quintero, Enrique Álvarez-Sánchez, Victoria Fernández-Bañares, Fernando Boadas, Jaume Campo, Rafel Bujanda, Luis Clofent, Joan Ferrandez, Ángel Torrealba, Leyanira Piñol, Virginia Rodríguez-Alcalde, Daniel Hernández, Vicent Fernández-Seara, Javier BMC Med Research Article BACKGROUND: Risk prediction models for colorectal cancer (CRC) detection in symptomatic patients based on available biomarkers may improve CRC diagnosis. Our aim was to develop, compare with the NICE referral criteria and externally validate a CRC prediction model, COLONPREDICT, based on clinical and laboratory variables. METHODS: This prospective cross-sectional study included consecutive patients with gastrointestinal symptoms referred for colonoscopy between March 2012 and September 2013 in a derivation cohort and between March 2014 and March 2015 in a validation cohort. In the derivation cohort, we assessed symptoms and the NICE referral criteria, and determined levels of faecal haemoglobin and calprotectin, blood haemoglobin, and serum carcinoembryonic antigen before performing an anorectal examination and a colonoscopy. A multivariate logistic regression analysis was used to develop the model with diagnostic accuracy with CRC detection as the main outcome. RESULTS: We included 1572 patients in the derivation cohort and 1481 in the validation cohorts, with a 13.6 % and 9.1 % CRC prevalence respectively. The final prediction model included 11 variables: age (years) (odds ratio [OR] 1.04, 95 % confidence interval [CI] 1.02–1.06), male gender (OR 2.2, 95 % CI 1.5–3.4), faecal haemoglobin ≥20 μg/g (OR 17.0, 95 % CI 10.0–28.6), blood haemoglobin <10 g/dL (OR 4.8, 95 % CI 2.2–10.3), blood haemoglobin 10–12 g/dL (OR 1.8, 95 % CI 1.1–3.0), carcinoembryonic antigen ≥3 ng/mL (OR 4.5, 95 % CI 3.0–6.8), acetylsalicylic acid treatment (OR 0.4, 95 % CI 0.2–0.7), previous colonoscopy (OR 0.1, 95 % CI 0.06–0.2), rectal mass (OR 14.8, 95 % CI 5.3–41.0), benign anorectal lesion (OR 0.3, 95 % CI 0.2–0.4), rectal bleeding (OR 2.2, 95 % CI 1.4–3.4) and change in bowel habit (OR 1.7, 95 % CI 1.1–2.5). The area under the curve (AUC) was 0.92 (95 % CI 0.91–0.94), higher than the NICE referral criteria (AUC 0.59, 95 % CI 0.55–0.63; p < 0.001). On the basis of the thresholds with 90 % (5.6) and 99 % (3.5) sensitivity, we divided the derivation cohort into three risk groups for CRC detection: high (30.9 % of the cohort, positive predictive value [PPV] 40.7 %, 95 % CI 36.7–45.9 %), intermediate (29.5 %, PPV 4.4 %, 95 % CI 2.8–6.8 %) and low (39.5 %, PPV 0.2 %, 95 % CI 0.0–1.1 %). The discriminatory ability was equivalent in the validation cohort (AUC 0.92, 95 % CI 0.90–0.94; p = 0.7). CONCLUSIONS: COLONPREDICT is a highly accurate prediction model for CRC detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0668-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-31 /pmc/articles/PMC5007726/ /pubmed/27580745 http://dx.doi.org/10.1186/s12916-016-0668-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cubiella, Joaquín Vega, Pablo Salve, María Díaz-Ondina, Marta Alves, Maria Teresa Quintero, Enrique Álvarez-Sánchez, Victoria Fernández-Bañares, Fernando Boadas, Jaume Campo, Rafel Bujanda, Luis Clofent, Joan Ferrandez, Ángel Torrealba, Leyanira Piñol, Virginia Rodríguez-Alcalde, Daniel Hernández, Vicent Fernández-Seara, Javier Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title | Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title_full | Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title_fullStr | Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title_full_unstemmed | Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title_short | Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
title_sort | development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007726/ https://www.ncbi.nlm.nih.gov/pubmed/27580745 http://dx.doi.org/10.1186/s12916-016-0668-5 |
work_keys_str_mv | AT cubiellajoaquin developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT vegapablo developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT salvemaria developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT diazondinamarta developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT alvesmariateresa developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT quinteroenrique developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT alvarezsanchezvictoria developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT fernandezbanaresfernando developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT boadasjaume developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT camporafel developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT bujandaluis developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT clofentjoan developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT ferrandezangel developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT torrealbaleyanira developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT pinolvirginia developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT rodriguezalcaldedaniel developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT hernandezvicent developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT fernandezsearajavier developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients AT developmentandexternalvalidationofafaecalimmunochemicaltestbasedpredictionmodelforcolorectalcancerdetectioninsymptomaticpatients |